Rohto Pharmaceutical Co.,Ltd.
Management Strategy Briefing 2026.10.02
Rolling update of the medium- to long-term growth strategy and disclosure of capital allocation policy. Strengthening business portfolios across eye care, skin care, oral supplements/ingestion, food, and medical segments, targeting net sales of 415 billion yen and operating income of 54 billion yen by fiscal 2030. Maintains and aims to expand shareholder returns with a dividend payout ratio of 30% or more and indicates plans to increase the overseas sales ratio.
Key Figures
- Net Sales: 3,086 hundred million yen (Fiscal 2024 actual) → Fiscal 2030 forecast 4,150 hundred million yen
- Operating Income: 382 hundred million yen (Fiscal 2024 actual) → Fiscal 2030 forecast 540 hundred million yen
- Overseas Sales Ratio: 47% (Fiscal 2024) → Fiscal 2030 forecast 53%
AI要約
Overview of Medium- to Long-Term Growth Strategy
Rohto Pharmaceutical Co.,Ltd. is performing a rolling update of its medium- to long-term growth strategy, focusing on growth of its core businesses—eye care and skin care—while expanding into new areas including oral supplements/ingestion, food, and medical fields. The company will promote value creation by leveraging technological capabilities and intellectual property and accelerate global expansion. It presented fiscal 2024 actual results and targets for fiscal 2030, planning to raise the overseas sales ratio to around 53%.
Shareholder Returns and Capital Policy Direction
As a capital policy, the company clarified reallocating cash allocation to balance growth investments and shareholder returns. It will continue a dividend payout ratio of 30% or more and indicated the possibility of targeting around 40% by 2030. The company intends to build the next-generation high-profit base through increased DX/IT investment and R&D expenditures.
Rohto Pharmaceutical Co.,Ltd.
Company overview · Stock price · Financial data · All IR
